ClinicalTrials.gg
CompletedNCT01444248Updated Aug 23, 2012

Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy

A Phase 4 interventional study of Glimepiride/ Metformin and Glimepiride/ Metformin in Type 2 Diabetes Mellitus, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-08-23.

Sponsored by Handok Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.

Enrollment
27th of 52
168 · median 169
Started
2010
with 2 others
Phase 4
24 of 52
none open now
Registered
26th of 52
by date
Lead sponsor
2 of 52
Handok Inc.

Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 3 that started in 2010, is one of 24 in phase 4, and was the 26th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing glimepiride in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study design of this trial is open-label, randomized, multi-center, parallel-group study.

Read the detailed description

The effectiveness of treatment of a disease depends mainly on two factors: the efficacy of the treatment and the compliance of the patient with this treatment. Polymedication is one of the predisposing factors to low compliance in type 2 DM. It can be expected that a simple regimen may improve compliance. Amaryl Mex phase III trial was not designed to compare the compliance of patients with different dosing regimens of oral antidiabetic drugs. However, it was found that patients' compliance in the morning was better than in the evening, suggesting that Amaryl Mex once daily regimen may improve compliance. Pill count is the gold standard for measuring compliance, but this method provides incomplete and unreliable results. Advanced electronic monitoring device obtains details of patients' behavior during the day and over long periods.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Amaryl MEX
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 \~ 75 years at screening
  • Patients who have been diagnosed with type 2 DM for at least 3 months
  • Patients who were treated with a stable dose with combination therapy of glimepiride 4mg or more and metformin 1000mg or more which can switch to Amaryl M 2/500mg bid or Amaryl Mex 2/500mg 2T od regimen.
  • ≤ 9 % at randomization
  • ≤ 40 kg/m2 at randomization
  • Patients who would give the
  • Patients who can perform SMBG and record the data on the patient's diary
  • Patients who can understand and use MEMS properly

Exclusion criteria

Exclusion Criteria:

  • Patients with the medical history of acute metabolic complications such as diabetic ketoacidosis, hyperosmolar nonketotic coma within 3 months prior to the study participation
  • Patients who are under insulin therapy at randomization
  • Patients who received systemic agent within 4 weeks prior to the study participation
  • Patients with acute, severe cardiovascular disease (e.g., heart failure, myocardial infarction, stroke, etc).
  • Pregnant or lactating females
  • history of drug or alcohol abuse
  • Patients with known to the ingredient of the study drug or drugs in sulfonylurea, sulfonamide, biguanide class
  • Night-shift workers
  • Patients with an experience of participating in other clinical trial within 3 months prior to the study participation
  • laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study based on investigator's decision
  • Patients with serum creatinine level > 1.5 mg/dl in male and > 1.4 mg/dl in female
  • Patients with or AST > 3x
  • Any conditions requiring help of others with drug administration (e.g. manual disability, serious visual defect, etc.)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Amaryl MEX

    Drug: Glimepiride/ Metformin

  • Active comparator
    Amaryl M

    Drug: Glimepiride/ Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. compliance of patients treated with once-daily or twice-daily

    Time frame: 24 weeks

Secondary outcomes

  1. Blood glucose lowering effect

    Time frame: 24 weeks

  2. Episodes of hypoglycaemia

    Time frame: 24 weeks

  3. other adverse events

    Time frame: 24 weeks

07

Study locations

1 site
  • Handok Pharmaceuticals
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Dec 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Sep 30, 2011
Start
Aug 2010
Primary completionActual
Dec 2011
CompletionActual
May 2012
Last update
Aug 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01444248
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Aug 2010
Primary completion
Dec 2011
Completion
May 2012
Last update
Aug 23, 2012

Study contacts

Sungwoo Park, professor
principal investigator · Kangbuk Samsung Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Metformin

Start the discussion